Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for t…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Yesterday | ||
Mendus AB (FRA:1YG0) (Q2 2026) Earnings Call Highlights: ADVANCE-II Validation and Strategic ... Mendus AB (FRA:1YG0) reports reduced costs and extended cash runway while advancing key trials in AML and CML, positioning for significant clinical milestones through 2027. | ||
Older | ||
Mendus AB (OSTO:IMMU) Q1 2026 Earnings Call Highlights: Clinical Progress and Strategic ... Mendus AB (OSTO:IMMU) advances in clinical trials and partnerships, while navigating recruitment hurdles in a competitive landscape. | ||
Mendus AB (STU:1YG0) Q4 2025 Earnings Call Highlights: Promising Trials and Financial Maneuvers ... Mendus AB (STU:1YG0) showcases positive trial data and strategic financial moves, despite facing ongoing financial hurdles and market uncertainties. | ||
Mendus AB (FRA:1YG0) Q3 2025 Earnings Call Highlights: Strategic Trials and Financial Challenges Mendus AB (FRA:1YG0) reports promising trial expansions and patent gains amidst financial hurdles and strategic adjustments. | ||
VVia TT | ||